Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel M Hoefner

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
MLO: Medical Laboratory Observer|January 27, 2006
Serum tumor markers. Part I: Clinical utilityDaniel M Hoefner
Clinica Chimica Acta; International Journal of Clinical Chemistry|May 17, 2006
New HDL-cholesterol reagent formulation reduces interference from samples with abnormal proteinsDaniel M Hoefner
MLO: Medical Laboratory Observer|April 6, 2006
Serum tumor markers: part II--practical considerations and limitations of testingDaniel M Hoefner
MLO: Medical Laboratory Observer|May 21, 2008
The cholesterol controversy continuesDaniel M Hoefner
MLO: Medical Laboratory Observer|October 24, 2003
The ruthless malady: metabolic syndromeDaniel M Hoefner
Clinics in Laboratory Medicine|August 30, 2006
Lipoprotein-associated phospholipase A2Joseph P McConnell, Daniel M Hoefner
Clinical Chemistry|August 27, 2002
Lot-to-lot inconsistency of anticardiolipin reagentsDaniel M Hoefner, Kiang-Teck J Yeo
BMJ Case Reports|October 16, 2015
Hypertriglyceridaemia unresponsive to multiple treatmentsJames M Backes, Thomas D Dayspring, Daniel M Hoefner, et al.
Clinical Chemistry|January 27, 2009
Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best PracticesJohn H Contois, Joseph P McConnell, Amar A Sethi, et al.
Journal of Clinical Lipidology|December 16, 2014
Lipoprotein(a) mass: a massively misunderstood metricJoseph P McConnell, Philip A Guadagno, Thomas D Dayspring, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
MLO: Medical Laboratory Observer|January 27, 2006
Serum tumor markers. Part I: Clinical utilityDaniel M Hoefner
Clinica Chimica Acta; International Journal of Clinical Chemistry|May 17, 2006
New HDL-cholesterol reagent formulation reduces interference from samples with abnormal proteinsDaniel M Hoefner
MLO: Medical Laboratory Observer|April 6, 2006
Serum tumor markers: part II--practical considerations and limitations of testingDaniel M Hoefner
MLO: Medical Laboratory Observer|May 21, 2008
The cholesterol controversy continuesDaniel M Hoefner
MLO: Medical Laboratory Observer|October 24, 2003
The ruthless malady: metabolic syndromeDaniel M Hoefner
Clinics in Laboratory Medicine|August 30, 2006
Lipoprotein-associated phospholipase A2Joseph P McConnell, Daniel M Hoefner
Clinical Chemistry|August 27, 2002
Lot-to-lot inconsistency of anticardiolipin reagentsDaniel M Hoefner, Kiang-Teck J Yeo
BMJ Case Reports|October 16, 2015
Hypertriglyceridaemia unresponsive to multiple treatmentsJames M Backes, Thomas D Dayspring, Daniel M Hoefner, et al.
Clinical Chemistry|January 27, 2009
Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best PracticesJohn H Contois, Joseph P McConnell, Amar A Sethi, et al.
Journal of Clinical Lipidology|December 16, 2014
Lipoprotein(a) mass: a massively misunderstood metricJoseph P McConnell, Philip A Guadagno, Thomas D Dayspring, et al.
Pageof 2